333 related articles for article (PubMed ID: 16120052)
1. Monoclonal antibody therapy of leukaemias and lymphomas.
Jacobs SA; Foon KA
Expert Opin Biol Ther; 2005 Sep; 5(9):1225-43. PubMed ID: 16120052
[TBL] [Abstract][Full Text] [Related]
2. Monoclonal antibody therapy for central nervous system lymphomas: an emerging treatment paradigm.
Wong ET
Expert Opin Pharmacother; 2005 Jun; 6(7):1107-14. PubMed ID: 15957965
[TBL] [Abstract][Full Text] [Related]
3. [Monoclonal antibody therapy targeting surface antigens of leukemic cells].
Meng FY; Fu YB
Zhonghua Yi Xue Za Zhi; 2005 Feb; 85(7):441-3. PubMed ID: 15854546
[No Abstract] [Full Text] [Related]
4. Monoclonal antibody therapy for lymphoma.
Campbell P; Marcus R
Blood Rev; 2003 Sep; 17(3):143-52. PubMed ID: 12818224
[TBL] [Abstract][Full Text] [Related]
5. A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL).
Nabhan C; Patton D; Gordon LI; Riley MB; Kuzel T; Tallman MS; Rosen ST
Leuk Lymphoma; 2004 Nov; 45(11):2269-73. PubMed ID: 15512816
[TBL] [Abstract][Full Text] [Related]
6. [Therapeutic monoclonal antibodies in onco-hematology].
Cartron G; Rossi JF
Med Sci (Paris); 2009 Dec; 25(12):1085-9. PubMed ID: 20035683
[TBL] [Abstract][Full Text] [Related]
7. Monoclonal antibodies in the treatment of cancer, Part 1.
Cersosimo RJ
Am J Health Syst Pharm; 2003 Aug; 60(15):1531-48. PubMed ID: 12951753
[TBL] [Abstract][Full Text] [Related]
8. Alemtuzumab in the treatment of chronic lymphocytic leukemia.
Robak T
BioDrugs; 2005; 19(1):9-22. PubMed ID: 15691213
[TBL] [Abstract][Full Text] [Related]
9. Alemtuzumab therapy in B-cell lymphoproliferative disorders.
Moreton P; Hillmen P
Semin Oncol; 2003 Aug; 30(4):493-501. PubMed ID: 12939718
[TBL] [Abstract][Full Text] [Related]
10. [Novel monoclonal antibodies for the treatment of malignant lymphomas].
Maruyama D
Rinsho Ketsueki; 2011 Aug; 52(8):618-26. PubMed ID: 21897067
[No Abstract] [Full Text] [Related]
11. Alemtuzumab in B-cell chronic lymphocytic leukemia.
Shapira I; Grossbard ML
Clin Lymphoma; 2004 Mar; 4(4):228-9. PubMed ID: 15072614
[No Abstract] [Full Text] [Related]
12. Monoclonal antibodies in the treatment of chronic lymphoid leukemias.
Robak T
Leuk Lymphoma; 2004 Feb; 45(2):205-19. PubMed ID: 15101704
[TBL] [Abstract][Full Text] [Related]
13. CD52 over-expression affects rituximab-associated complement-mediated cytotoxicity but not antibody-dependent cellular cytotoxicity: preclinical evidence that targeting CD52 with alemtuzumab may reverse acquired resistance to rituximab in non-Hodgkin lymphoma.
Cruz RI; Hernandez-Ilizaliturri FJ; Olejniczak S; Deeb G; Knight J; Wallace P; Thurberg BL; Kennedy W; Czuczman MS
Leuk Lymphoma; 2007 Dec; 48(12):2424-36. PubMed ID: 18067019
[TBL] [Abstract][Full Text] [Related]
14. A novel Raji-Burkitt's lymphoma model for preclinical and mechanistic evaluation of CD52-targeted immunotherapeutic agents.
Lapalombella R; Zhao X; Triantafillou G; Yu B; Jin Y; Lozanski G; Cheney C; Heerema N; Jarjoura D; Lehman A; Lee LJ; Marcucci G; Lee RJ; Caligiuri MA; Muthusamy N; Byrd JC
Clin Cancer Res; 2008 Jan; 14(2):569-78. PubMed ID: 18223233
[TBL] [Abstract][Full Text] [Related]
15. AntiCD20 mAbs: modifying therapeutic strategies and outcomes in the treatment of lymphoma patients.
Grillo-López AJ
Expert Rev Anticancer Ther; 2002 Jun; 2(3):323-9. PubMed ID: 12113055
[TBL] [Abstract][Full Text] [Related]
16. Effect of alemtuzumab on neoplastic B cells.
Golay J; Manganini M; Rambaldi A; Introna M
Haematologica; 2004 Dec; 89(12):1476-83. PubMed ID: 15590398
[TBL] [Abstract][Full Text] [Related]
17. ["Magic bullets"--monoclonal antibodies in acute leukemia and non-Hodgkin's lymphoma treatment].
Łuczyński W; Krawczuk-Rybak M
Postepy Hig Med Dosw; 2002; 56(6):789-801. PubMed ID: 12669700
[TBL] [Abstract][Full Text] [Related]
18. Conceptual aspects of combining rituximab and Campath-1H in the treatment of chronic lymphocytic leukemia.
Nabhan C; Rosen ST
Semin Oncol; 2002 Feb; 29(1 Suppl 2):75-80. PubMed ID: 11842392
[TBL] [Abstract][Full Text] [Related]
19. [Monoclonal antibodies in hematology in 2009].
Bonnet C; Beguin Y; De Prijck B; Witvrouw N; Hustinx R; Fillet G
Rev Med Liege; 2009; 64(5-6):268-73. PubMed ID: 19642457
[TBL] [Abstract][Full Text] [Related]
20. A mechanistic rationale for combining alemtuzumab and rituximab in the treatment of ALL.
Nijmeijer BA; van Schie ML; Halkes CJ; Griffioen M; Willemze R; Falkenburg JH
Blood; 2010 Dec; 116(26):5930-40. PubMed ID: 20844239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]